학술논문
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase
Document Type
Article
Author
Source
In Leukemia Research September 2015 39(9):950-956
Subject
Language
ISSN
0145-2126